NCT00190424已完成2 期
Multicentric Randomized Phase 2. Immunotherapy With CpG-ODN in Malignant Glioblastoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 80
- 试验地点
- 2
- 主要终点
- Survival
研究概览
简要总结
The purpose of this study is to determine whether the immunostimulating agent CpG-ODN is effective in the treatment of glioblastoma
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Glioblastoma
- •Karnofsky Performance Status ≥ 60%
排除标准
- •Severe or uncontrolled systemic disease
- •Active auto-immune disease
- •Uncontrolled epilepsia
- •Platelets < 100 000/mm3 ; or Neutrophils <500 /mm3 ; or lymphocytes <300/ mm3
研究组 & 干预措施
CpG-ODN
Experimental
干预措施: CpG-ODN (Drug)
结局指标
主要结局
Survival
时间窗: 2 years
次要结局
- Tolerance(2 years)
- Progression-free survival(2 years)
研究者
研究点 (2)
Loading locations...
相似试验
终止
2 期
Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)Ulcerative ColitisNCT00307827Abbott38
进行中（未招募）
2 期
A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast CancerBreast CancerNCT05852691Hoffmann-La Roche83
已完成
不适用
Phase 1/2 study of Multiple-Vaccine with CpG-ODN Therapy in Patient with Refractory Colon Cancer to Chemotherapy.Colon CancerJPRN-UMIN000002392Institute of Medical Science, The university of Tokyo.25
已完成
2 期
Study in Children to Evaluate the Immunogenicity and Safety of 4 Formulations of GSK Bio MenACWY-TT Conjugate VaccineInfections, MeningococcalNCT00126984GlaxoSmithKline508
已完成
2 期
Efficacy and Safety Study of KN019 in Rheumatoid Arthritis Patients With an Inadequate Response to MethotrexateRheumatoid ArthritisNCT04038970Jiangsu Alphamab Biopharmaceuticals Co., Ltd145